Therapeutic Asset Ratings

223 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Adebrelimab Lung Cancer	Hansoh BioMedical R&D Company	P2	CCC (52)
Dostarlimab Lung Cancer	iTeos Belgium SA	P2	CCC (52)
Ensartinib Lung Cancer	Sun Yat-sen University	P2	CCC (52)
Lorlatinib Lung Cancer	SCRI Development Innovations, LLC	P2	CCC (52)
Pemigatinib Lung Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CCC (52)
Sacituzumab Tirumotecan Lung Cancer	Merck Sharp & Dohme LLC	P2	CCC (52)
Ceritinib Lung Cancer	National Cancer Institute (NCI)	P2	CCC (51)
Defactinib Lung Cancer	Emory University	P2	CCC (51)
Denosumab Lung Cancer	Shanghai Pulmonary Hospital, Shanghai, China	P2	CCC (51)
Domvanalimab Lung Cancer	Arcus Biosciences, Inc.	P2	CCC (51)
Etrumadenant Lung Cancer	Gilead Sciences	P2	CCC (51)
Hydroxychloroquine Lung Cancer	N.N. Petrov National Medical Research Center of Oncology	P2	CCC (51)
Romiplostim Lung Cancer	Peking University People's Hospital	P2	CCC (50)
[18f]f-resca-rt4 Lung Cancer	RenJi Hospital	P2/3	CCC (50)
[18F]F-RESCA-T4 Lung Cancer	RenJi Hospital	P2/3	CCC (50)
[68ga]ga-nota-rt4 Lung Cancer	RenJi Hospital	P2/3	CCC (50)
[68ga]ga-nota-t4 Lung Cancer	RenJi Hospital	P2/3	CCC (50)
Iodixanol Lung Cancer	Brian Henick, MD	P1/2	CCC (49)
Aguix Lung Cancer	Brigham and Women's Hospital	P2	CCC (48)
BENZAMIDE, 3-((3-ENDO)-8-(2-((CYCLOHEXYLMETHYL)((2S)-2,3-DIHYDROXY-1-OXOPROPYL)AMINO)ETHYL)-8-AZABICYCLO(3.2.1)OCT-3-YL)- Lung Cancer	HealthPartners Institute	P2	CCC (48)
Cobimetinib Lung Cancer	N.N. Petrov National Medical Research Center of Oncology	P2	CCC (48)
Datopotamab Deruxtecan Lung Cancer	Latin American Cooperative Oncology Group	P2	CCC (48)
Ezetimibe Lung Cancer	Jinghui Wang	P2	CCC (48)
her3-dxd Lung Cancer	Daiichi Sankyo	P2	CCC (48)
Hrs-4508 Lung Cancer	Jiangsu HengRui Medicine Co., Ltd.	P2	CCC (48)

Showing 76 to 100 of 223 assets

PreviousPage 4 of 9Next